Indoximod

SKU: orb1300675

Description

Indoximod (NLG-8189) is a methylated tryptophan analog that acts as an immune checkpoint inhibitor by targeting indoleamine 2,3-dioxygenase (IDO). Its inhibition of IDO prevents tryptophan depletion, thereby countering T-cell anergy and immunosuppression. This small molecule is utilized in both in vitro and in vivo research to study cancer immunotherapy, autoimmune diseases, and T-cell function.

Research Area

Immunology & Inflammation

Key Properties

• CAS Number: 110117-83-4
• MW: 218.25
• Purity: >98%
• Formula: C₁₂H₁₄N₂O₂
• SMILES: Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12
• Target: Tryptophan
• Solubility: Soluble in DMSO (greater than 25 mg/ml).

Bioactivity

• Target IC50:
  IDO:19 μM(Ki)
• In Vivo:
  In mouse models of transplantable melanoma and transplantable and autochthonous breast cancer, Indoximod (400 mg/kg p.o.) enhances antitumor immunity in the setting of combined chemo-immunotherapy regimens.
• In Vitro:
  Indoximod significantly reverses the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte-derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes. Indoximod activates a Trp sufficiency signal that stimulates mTOR, and relieves IDO-induced Trp deprivation as well as an autophagic response.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

tryptophan, Trp mimetic, Inhibitor, IDO, NLG 8189, NLG8189, NLG-8189, mTORC1, Indoleamine 2,3-Dioxygenase, Indoleamine 2,3Dioxygenase (IDO), Indoleamine 2,3-Dioxygenase (IDO), Indoleamine2,3Dioxygenase, Indoleamine2,3Dioxygenase(IDO), Indoximod, Indoximod (NLG-8189), immunotherapeutic vaccines, inhibit, cancer, 1-Methyl-D-tryptophan

Compound Identifiers

PubChem CID

405012